National Research Corporation
NASDAQ:NRCMedical - Healthcare Information Services
+$0.07 today
- Market cap
- $555.16M
- Beta
- 0.40
- P/E (TTM)
- 43.0
- EPS (TTM)
- $0.41
- Dividend yield
- 3.14%
Volume 0.09M
Average 0.11M
NRC EBITDA Margin
EBITDA as a percentage of revenue.
National Research CorporationNASDAQ: NRC
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin narrows to 22.4%
EBITDA Margin was 22.4% in Q1 FY2026, down 7.9 pp from a year earlier. On a trailing-twelve-month basis it was 20.1%, down 9.1 pp year over year. Over 3 fiscal years it narrowed by 10.5 pp.
Context
- EBITDA Margin widened in 0 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 1 analysts of 32.1% for the fiscal year ending Dec 2026, up from 22.0% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 22.4%+3.1 pp QoQ
- Last fiscal yearDec 2025
- 22.0%-6.9 pp YoY
- LTMMar 2026
- 20.1%-9.1 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -7.9 pp | -9.4 pp | -1.5 pp |
| 1 year | -6.9 pp | +10.1 pp | +17.0 pp |
| 3 years | -10.5 pp | +14.4 pp | +24.9 pp |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 22.0%
- Year-over-year change
- -6.9pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 22.0% | -6.9pp |
| FY2024 | 2024-12-31 | 28.9% | -2.1pp |
| FY2023 | 2023-12-31 | 30.9% | -1.6pp |
| FY2022 | 2022-12-31 | 32.5% | -5.8pp |
| FY2021 | 2021-12-31 | 38.3% | — |
EBITDA Margin vs competitors
How NRC compares with its peers on the latest reported figures
- NRC's LTM Mar 2026 EBITDA Margin of 20.1% is the 4th highest of the 8 companies compared; the peer median is 8.6%.
- Its year-over-year change of -9.1 pp is the 7th highest of 8, against a peer median of +1.3 pp.
- Over three fiscal years its change of -10.5 pp compares with a peer median of +8.3 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
CTEVClaritev Corporation | LTM Mar 2026 | 52.9% | +109.3 pp | +34.6 pp |
| LTM Mar 2026 | 22.8% | +1.3 pp | +8.3 pp | |
| LTM Mar 2026 | 22.4% | +0.1 pp | +1.9 pp | |
| LTM Mar 2026 | 20.1% | -9.1 pp | -10.5 pp | |
| LTM Apr 2026 | 8.6% | +10.7 pp | +57.9 pp | |
| LTM Mar 2026 | 4.9% | +295.3 pp | -78.9 pp | |
| LTM Mar 2026 | -63.6% | -59.1 pp | -5.5 pp | |
| LTM Mar 2026 | -81.4% | -6.3 pp | +87.8 pp | |
| Peer median (excluding NRC) | 8.6% | +1.3 pp | +8.3 pp | |
Competitors are the stored peer set for NRC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 147.95M | 151.57M | 148.58M | 143.06M | 137.39M |
| Cost of Revenue | 52.35M | 57.05M | 56.02M | 56.93M | 60M |
| Gross Profit | 95.6M | 94.52M | 92.57M | 86.13M | 77.4M |
| Gross Margin | 64.6% | 62.4% | 62.3% | 60.2% | 56.3% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 38.96M | 42.7M | 46.58M | 44.91M | 54.81M |
| Operating Expenses | 45.33M | 47.98M | 52.52M | 50.93M | 54.81M |
| Depreciation & Amortization | 6.37M | 5.28M | 5.9M | 6.02M | 7.62M |
| EBITDA | 56.66M | 49.3M | 45.99M | 41.31M | 30.23M |
| EBITDA Margin | 38.3% | 32.5% | 30.9% | 28.9% | 22.0% |
| Operating Income | 50.27M | 46.54M | 40.05M | 35.19M | 22.59M |
| Operating Margin | 34.0% | 30.7% | 27.0% | 24.6% | 16.4% |
| Interest Income | 14K | 168K | 820K | 125K | 111K |
| Interest Expense | 1.67M | 1.21M | 862K | 2.6M | 4.76M |
| Other Income / Expenses | (1.65M) | (3.73M) | (83K) | (2.5M) | (4.75M) |
| Income Before Tax | 48.62M | 42.82M | 39.96M | 32.69M | 17.84M |
| Pre-Tax Margin | 32.9% | 28.2% | 26.9% | 22.9% | 13.0% |
| Income Tax Expense | 11.16M | 11.02M | 8.99M | 7.91M | 6.24M |
| Net Income | 37.47M | 31.8M | 30.97M | 24.78M | 11.6M |
| Net Margin | 25.3% | 21.0% | 20.8% | 17.3% | 8.4% |
| EPS (Basic) | 1.47 | 1.28 | 1.26 | 1.05 | 0.52 |
| EPS (Diluted) | 1.46 | 1.27 | 1.25 | 1.04 | 0.52 |
| Weighted Avg Shares | 25.42M | 24.92M | 24.54M | 23.72M | 22.38M |
| Weighted Avg Shares (Diluted) | 25.64M | 25.05M | 24.67M | 23.74M | 22.4M |
National Research Corporation
NASDAQ:NRC
Intrinsic Alpha fair value
Locked
Current Price
$26.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.